HER2 and response to paclitaxel in node-positive breast cancer

New England Journal of Medicine

Volumn 357, Issue 15, 2007, Pages 1496-1506

  Hayes, Daniel F ^a,n   Thor, Ann D ^b   Dressler, Lynn G ^c   Weaver, Donald ^d   Edgerton, Susan ^b   Cowan, David ^c   Broadwater, Gloria ^e   Goldstein, Lori J ^f   Martino, Silvana ^g   Ingle, James N ^h   Henderson, I Craig ⁱ   Norton, Larry ^j   Winer, Eric P ^k   Hudis, Clifford A ^j   Ellis, Matthew J ^l   Berry, Donald A ^m  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e DUKE UNIVERSITY   (United States)

^f Philadelphia Fox Chase Cancer Centre   (United States)

^g Angeles Clinic and Research Institute   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l USA   (United States)

^m UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁿ UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PACLITAXEL; POLYCLONAL ANTIBODY; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BODY SURFACE; BREAST CANCER; CANCER RECURRENCE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT RESPONSE; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PACLITAXEL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 35248895346     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa071167     Document Type: Article

References (42)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
2. Smith I, Chua S. Medical treatment of early breast cancer. I. Adjuvant treatment. BMJ 2006;332:34-7.
3. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-9. [Erratum, N Engl J Med 1994;331:139.]
4. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998;90:1205-11.
5. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
7. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005;6:240-6.
8. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56.
9. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6. [Erratum, N Engl J Med 1994;331:211.]
10. Thor AD, Berry DA, Budman DR, et al. erbB2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-60.
11. Dressler LG, Berry DA, Broadwater G, et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005;23:4287-97.
12. Yu D. Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol 2001;28:Suppl 16:12-7.
13. Formenti SC, Spicer D, Skinner K, et al. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 2002;52:397-405.
14. Sjöström J, Collan J, von Boguslawski K, et al. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 2002;38:535-42.
15. Tulbah AM, Ibrahim EM, Ezzat AA, et al. HER-2/neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer. Med Oncol 2002;19:15-23.
16. Van Poznak C, Tan L, Panageas KS, et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002;20:2319-26.
17. Schmidt M, Bachhuber A, Victor A, et al. p53 Expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol 2003;129:295-302.
18. Witters LM, Santala SM, Engle L, Chinchilli V, Lipton A. Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells. Am J Clin Oncol 2003;26:50-4.
19. Konecny GE, Thomssen C, Lück HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004;96:1141-51.
20. Di Leo A, Chan S, Paesmans M, et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 2004;86:197-206.
21. Gonzalez-Angulo AM, Krishnamurthy S, Yamamura Y, et al. Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 2004;101:258-63.
22. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
23. Sezgin C, Karabulut B, Uslu R, et al. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. J Chemother 2005;17:96-103.
24. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-4.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-72.
26. Lippman ME, Allegra JC, Thompson EB, et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 1978;298:1223-8.
27. Regan MM, Gelber RD. Predicting response to systemic treatments: learning from the past to plan for the future. Breast 2005;14:582-93.
28. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-67. [Erratum, JAMA 2006;295:2356.]
29. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
30. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18.
31. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9. [Erratum, J Clin Oncol 2003;21:2226.]
32. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-11.
33. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 1997;15:953-60.
34. Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000;27:Suppl 11:21-5.
35. Ueno NT, Bartholomeusz C, Herrmann JL, et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000;6:250-9.
36. Bacus SS, Gudkov AV, Lowe M, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001;20:147-55.
37. Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol 2003;22:875-81.
38. Abuharbeid S, Apel J, Zugmaier G, et al. Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol 2005;371:141-51.
39. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
40. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
41. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER-2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94:S5. abstract.
42. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.